Jonathan D. Hoang

Jonathan D. Hoang

Auto-generated profile, based on publicly available information

Jonathan D. Hoang

UCLA Electrophysiology Programs, Division of Cardiology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
JHJonathan D. Hoang
Jonathan D. Hoang
SSSiamak Salavatian
Siamak Salavatian
NYNaoko Yamaguchi
Naoko Yamaguchi
MSMohammed Amer Swid
Mohammed Amer Swid
DHDavid Hamon
David Hamon
MVMarmar Vaseghi
Marmar Vaseghi
The sympathetic nervous system plays an important role in the occurrence of ventricular tachycardia (VT). Many patients, however, experience VT despite maximal doses of beta blocker therapy, possibly due to the effects of sympathetic cotransmitters such as neuropeptide Y (NPY). The purpose of this study was to determine, in a porcine model, whether propranolol at doses higher than clinically recommended could block ventricular electrophysiological effects of sympathoexcitation via stellate ganglia stimulation, and if any residual effects are mediated by NPY. Greater release of cardiac NPY was observed at higher sympathetic stimulation frequencies (10 and 20 vs. 4 Hz). Despite treatment with even higher doses of propranolol (1.0 mg/kg), electrophysiological effects of sympathetic stimulation remained, with residual shortening of activation recovery interval (ARI), a surrogate of action potential duration (APD). Adjuvant treatment with the NPY Y 1 receptor antagonist BIBO 3304, however, reduced these electrophysiological effects while augmenting inotropy. These data demonstrate that high-dose beta blocker therapy is insufficient to block electrophysiological effects of sympathoexcitation, and a portion of these electrical effects in vivo are mediated by NPY. Y 1 receptor blockade may represent a promising adjuvant therapy to beta-adrenergic receptor blockade.

22 February 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
SSSiamak Salavatian
Siamak Salavatian
JHJonathan D. Hoang
Jonathan D. Hoang
NYNaoko Yamaguchi
Naoko Yamaguchi
ZLZulfiqar Ali Lokhandwala
Zulfiqar Ali Lokhandwala
MSMohammed Amer Swid
Mohammed Amer Swid
MVMarmar Vaseghi
Marmar Vaseghi
Myocardial infarction causes pathological changes in the autonomic nervous system, which exacerbate heart failure and predispose to fatal ventricular arrhythmias and sudden death. These changes are characterized by sympathetic activation and parasympathetic dysfunction (reduced vagal tone). Reasons for the central vagal withdrawal and, specifically, whether myocardial infarction causes changes in cardiac vagal afferent neurotransmission that then affect efferent tone, remain unknown. The objective of this study was to evaluate whether myocardial infarction causes changes in vagal neuronal afferent signaling. Using in vivo neural recordings from the inferior vagal (nodose) ganglia and immunohistochemical analyses, structural and functional alterations in vagal sensory neurons were characterized in a chronic porcine infarct model and compared with normal animals. Myocardial infarction caused an increase in the number of nociceptive neurons but a paradoxical decrease in functional nociceptive signaling. No changes in mechanosensitive neurons were observed. Notably, nociceptive neurons demonstrated an increase in GABAergic expression. Given that nociceptive signaling through the vagal ganglia increases efferent vagal tone, the results of this study suggest that a decrease in functional nociception, possibly due to an increase in expression of inhibitory neurotransmitters, may contribute to vagal withdrawal after myocardial infarction.

1 January 2022 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
JHJoseph Hadaya
Joseph Hadaya
UBUna Buckley
Una Buckley
NGNil Z. Gurel
Nil Z. Gurel
CCChristopher A. Chan
Christopher A. Chan
MSMohammed A. Swid
Mohammed A. Swid
JAJeffrey L. Ardell
Jeffrey L. Ardell
Maladaptation of the sympathetic nervous system contributes to the progression of cardiovascular disease and risk for sudden cardiac death, the leading cause of mortality worldwide. Axonal modulation therapy (AMT) directed at the paravertebral chain blocks sympathetic efferent outflow to the heart and maybe a promising strategy to mitigate excess disease-associated sympathoexcitation. The present work evaluates AMT, directed at the sympathetic chain, in blocking sympathoexcitation using a porcine model. In anesthetized porcine (n = 14), we applied AMT to the right T1-T2 paravertebral chain and performed electrical stimulation of the distal portion of the right sympathetic chain (RSS). RSS-evoked changes in heart rate, contractility, ventricular activation recovery interval (ARI), and norepinephrine release were examined with and without kilohertz frequency alternating current block (KHFAC). To evaluate efficacy of AMT in the setting of sympathectomy, evaluations were performed in the intact state and repeated after left and bilateral sympathectomy. We found strong correlations between AMT intensity and block of sympathetic stimulation-evoked changes in cardiac electrical and mechanical indices (r = 0.83–0.96, effect size d = 1.9–5.7), as well as evidence of sustainability and memory. AMT significantly reduced RSS-evoked left ventricular interstitial norepinephrine release, as well as coronary sinus norepinephrine levels. Moreover, AMT remained efficacious following removal of the left sympathetic chain, with similar mitigation of evoked cardiac changes and reduction of catecholamine release. With growth of neuromodulation, an on-demand or reactionary system for reversible AMT may have therapeutic potential for cardiovascular disease-associated sympathoexcitation. NEW & NOTEWORTHY Autonomic imbalance and excess sympathetic activity have been implicated in the pathogenesis of cardiovascular disease and are targets for existing medical therapy. Neuromodulation may allow for control of sympathetic projections to the heart in an on-demand and reversible manner. This study provides proof-of-concept evidence that axonal modulation therapy (AMT) blocks sympathoexcitation by defining scalability, sustainability, and memory properties of AMT. Moreover, AMT directly reduces release of myocardial norepinephrine, a mediator of arrhythmias and heart failure.

20 October 2025 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
LMLivia H. Morais
Livia H. Morais
LSLinsey Stiles
Linsey Stiles
MFMilla Freeman
Milla Freeman
AOAnastasiya D. Oguienko
Anastasiya D. Oguienko
JHJonathan D. Hoang
Jonathan D. Hoang
SMSarkis K. Mazmanian
Sarkis K. Mazmanian
The pathophysiology of Parkinson’s disease (PD) involves gene-environment interactions that impair various cellular processes including mitochondrial dysfunction. Mitochondria-associated mutations increase PD risk, respiration is altered in the PD brain, and mitochondria-damaging toxicants cause PD-like motor and gastrointestinal symptoms in animal models. The gut microbiome is altered in PD, representing an environmental risk, however a relationship between mitochondrial function and the microbiome in PD has not been previously established. Herein, we discover that dysregulation of mitochondria-associated genes and hyperactive striatal mitochondria are induced by the microbiome in α-synuclein-overexpressing (Thy1-ASO) mice. Thy1-ASO mice elaborate increased reactive oxygen species in the striatum whereas germ-free counterparts express increased oxygen scavenging proteins. Indeed, treatment with an antioxidant drug improves motor performance in Thy1-ASO mice and blocking oxidant scavenging in germ-free mice enhances motor deficits in an α-synuclein dependent manner. Thus, the gut microbiome promotes motor symptoms in a mouse model of PD via increased mitochondrial respiration and oxidative stress in the brain.

1 September 2024 in Physiological Genomics
Verified
Journal Article
Closed access
TGTatyana Gurlo
Tatyana Gurlo
RLRuoshui Liu
Ruoshui Liu
ZWZhongying Wang
Zhongying Wang
JHJonathan Hoang
Jonathan Hoang
SRSergey Ryazantsev
Sergey Ryazantsev
PBPeter C. Butler
Peter C. Butler
β-Cell failure in type 2 diabetes (T2D) is characterized by β-cell misfolded protein stress due to the formation of toxic oligomers of islet amyloid polypeptide (IAPP). Most transcriptional changes in islets in T2D are pro-survival adaptations consistent with the slow progression of β-cell loss. In the present study, investigation of the islet transcriptional signatures in a mouse model of T2D expressing human IAPP revealed decreased cholesterol synthesis and trafficking as a plausible early mediator of IAPP toxicity.

8 June 2018 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
JHJonathan D. Hoang
Jonathan D. Hoang
MVMarmar Vaseghi
Marmar Vaseghi